MaaT Pharma updates potential plan for MaaT013 after CHMP negative
MaaT Pharma said the EMA’s CHMP issued a negative opinion after re-examination of MaaT013 (Xervyteg®) and the company provided an update on a potential development plan.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.